Indifferently pursued or unowned drugs: Who should lead where companies do not tread?

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1796-1798

  Sausville, Edward A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; FENRETINIDE; FLUOROURACIL; GEFITINIB; SAFINGOL; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EDITORIAL; HUMAN; LUNG CANCER; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; DRUG MANUFACTURE; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; DRUG INDUSTRY; HUMANS; NEOPLASMS; ORPHAN DRUG PRODUCTION; PROTEIN KINASE INHIBITORS; STAUROSPORINE;

EID: 15744384553     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.963     Document Type: Editorial

References (23)

1. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 96:990-997, 2004
2. Adams J, Kauffman M: Development of the proteosome inhibitor Velcade (Bortezomib). Cancer Invest 22:304-311, 2004
3. El-Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 91:418-424, 2004
4. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
6. Kortmansky J, Shah MA, Kaubisch A, et al: Phase I trial of the cyclin-dependent kinase inhibitor/protein kinase C inhibitor UCN-01 in combination with 5FU in patients with advanced solid tumors. J Clin Oncol 23:1875-1884, 2005
7. Hsueh CT, Kelsen D, Schwartz GK: UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent fashion. Clin Cancer Res 4:2201-2206, 1998
8. Hsueh CT, Wu YC, Schwartz GK: UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. Clin Cancer Res 7:669-674, 2001
9. Hillenbrand A, Formentini A, Staib L, et al: A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumors receiving hepatic arterial infusion therapy. Eur J Surg Oncol 30:407-413, 2004
10. Sausville EA, Arbuck SG, Messmann R, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333, 2001
11. Hakimian RR, Edelman MJ, Bauer K, et al: Phase I and pharmacokinetic study of the cyclin dependent kinase inhibitor UCN-01 and carboplatin in solid tumors. Proc Am Soc Clin Oncol 22:149, 2003 (abstr 598)
12. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic anti-neoplastic agents. J Clin Oncol 20:4478-4484, 2002
13. Takahashi I, Saitoh Y, Yoshida M, et al: UCN-01 and UCN-02, new selective inhibitors of protein kinase C: II. Purification, physicochemical properties, structural determination, and biological activities. J Antibiot (Tokyo) 42:571-576, 1989
14. Saenaeve CM, Kazanietz M, Blumberg P, et al: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45:1207-1214, 1994
15. Wang Q, Worland PJ, Clark JL, et al: Apoptosis in 7-hydroxystaurosporine- treated T lymphoblasts correlates with activation of cyclin dependent kinases 1 and 2. Cell Growth Differ 6:927-936, 1995
16. Akiyama T, Yoshida T, Tsujita T, et al: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of RB and CDK2 proteins as well as induction of CDK1 inhibitor p21/Cip1/WAF1/Sdi 1 in p53 mutated human epidermoid carcinoma A431 cells. Cancer Res 57:1495-1501, 1997
17. Graves PR, Yu L, Schwartz JK, et al: The chk1 protein kinase and the cdc25C regulatory pathway are targets of the anti-cancer agent UCN-01. J Biol Chem 275:5600-5605, 2000
18. Yu Q, LaRose J, Zhang H, et al: UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases chk2 and chk1. Cancer Res 62:5743-5748, 2002
19. Monks A, Harris ED, Vaigro-Wolff A, et al: UCN01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 18:95-107, 2000
20. Sato S, Fujita N, Tsuruo T: Interference with PDK1-Akt signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21:1727-1738, 2002
21. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963, 2004
22. Wang H, Mauer BJ, Reynolds CP, et al: N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate inactivation of serine palmitoyltransferase ceramide synthase. Cancer Res 61:5102-5105, 2001
23. Schwartz GK, Ward D, Saltz L, et al: A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 3:537-543, 1997